Tag - COCP

Developments

Cocrystal showcases potential first oral antiviral for norovirus

Cocrystal Pharma (NASDAQ: COCP) has announced that the scientific foundation and clinical progress of its lead pan-viral protease inhibitor, CDI-988, was discussed by President and CEO, Dr. Sam Lee, in a presentation at...

September 12, 2025

Feature

Cocrystal Pharma advancing programs in high-value antiviral drug targets

With a drug discovery technology platform developed by several Nobel Prize laureates, Cocrystal Pharma (NASDAQ:COCP) is advancing broad spectrum antivirals in three programs: coronaviruses and variants, pandemic and...

April 5, 2022

Tag - COCP

Cocrystal showcases potential first oral antiviral for norovirus

Cocrystal Pharma advancing programs in high-value antiviral drug targets

Subscribe